Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476423 · ClinicalTrials.gov registry record
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 218
- Enrollment target
NCT01476423 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 218 participants.
The verdict
NCT01476423 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 218 participants
- Enrollment target
Study Summary
This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA). The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during invasive procedures/surgery in patients with Glanzmann's thrombasthenia (GT) with past or present refractoriness to platelet transfusions. Attention will be directed towards complications related to thrombo-embolic events and concomitant medications especially antifibrinolytics.
Interventions
- DRUG activated recombinant human factor VII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476423
The ClinicalTrials.gov registry entry for NCT01476423 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT01476423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476423 about?
NCT01476423 is a clinical study titled "Observational Registry of the Treatment of Glanzmann's Thrombasthenia". This observational registry is conducted in Europe, Asia, Africa and the United States of America (USA). The purpose of the registry is to evaluate the efficacy and safety of activated recombinant human factor VII (rFVIIa) during bleeding episodes and for the prevention of bleeding during invasive ...
What is the current status of trial NCT01476423?
This trial is currently completed. The enrollment target is 218 participants. The study started on 2004-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01476423?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT01476423?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.